Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Life Sciences Index Present Pharma Integrates 2013

Published: Monday, April 08, 2013
Last Updated: Monday, April 08, 2013
Bookmark and Share
Strategically transforming Pharma business relationships.

•    Pharma Integrates 2013 will be held on Tuesday 26th and Wednesday 27th November at the Riverbank Park Plaza, London. Further details available at

•    Following the success of the inaugural Pharma Integrates 2012, PI 2013 will retain the one and a half day conference format. Chairman Professor Trevor Jones CBE, Director Allergan & President of Sigma Tau Pharmaceuticals will be opening the half day series of keynotes and plenary panel discussions. The second day will include multiple tracks, with the majority of the sessions being interactive panel discussions to stimulate information exchange and organic discussion.

•    The overarching theme of Pharma Integrates is ‘Strategically transforming Pharma business relationships’,  with presentations and panel discussions addressing key industry issues from both an early and late product life cycle perspective. In 2013, we will examine how strategic relationships are evolving and increasingly becoming a source of mutual competitive advantage. Further how such collaborations are supporting innovation, productivity, differentiation and profitable growth. Topics to be addressed will include Risk Sharing, Biosimilars, Pricing, Partnering, Open Innovation and Pharma Intellectual Property.

•    Further details of Day One and Day Two Agenda available here:

What to expect from Pharma Integrates 2013

•    Unique panel discussion format ensuring the ultimate interactive experience.

•    Blockbuster topics that straddle a complementary profile of industry stakeholders.

•    Strategically led content dedicated to senior level strategists

•    Unrivalled networking opportunities with champagne reception, luncheon and extended breaks throughout the conference timetable.

Attendee Feedback from Pharma Integrates 2012

“Relevant, good speakers, right size. Made many new contacts – thanks!” Neil Baker, Pfizer.

“Nothing similar in the EU. Panel discussion approach very successful.” Laura Walsh, 3M.

“The event attracted high level delegates and decision makers and was very informal. Good presentations, very entertaining.” Heather Brunyee, Wockhardt.

“Enjoyed the level of attendees, good mix of stakeholders- all with a passion to improve the industry. We now need to deliver!” David Tudbury, Catalent.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Scientists Test New Gene Therapy for Vision Loss from a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
HIV Patients Should Be Included in Early Clinical Trials of Anti-TB Drugs
Tuberculosis is the number one cause of death in HIV-infected patients in Africa and a leading cause of death in this population worldwide.
Multi-Gene Test Enables Some Breast Cancer Patients to Safely Avoid Chemotherapy
A major study is providing the best evidence to date that a 21-gene test done on the tumor can identify breast cancer patients who can safely avoid chemotherapy.
Low Dose Beta-Blockers As Effective As High Dose After a Heart Attack?
Heart attack patients live as long – or even longer – on one-quarter the suggested dose.
Antidepressants Plus Blood-Thinners Slow Down Brain Cancer
EPFL scientists have found that combining antidepressants with anticoagulants slows down brain tumors (gliomas) in mice.
Old Drug Performs New Tricks
Cambridge-led research reveals the powers of a "wonder drug" that has lain under the noses of doctors for 50 years.
Electronic Reminders Keep TB Patients on Track With Medication In China
Giving electronic reminders to tuberculosis (TB) patients in China can reduce the amount of medication doses they miss by half, according to new research.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos